BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stake Lessened by Ameriprise Financial Inc.

Ameriprise Financial Inc. cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,720,581 shares of the biotechnology company's stock after selling 51,920 shares during the period. Ameriprise Financial Inc. owned about 0.83% of BioCryst Pharmaceuticals worth $12,939,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the period. Caligan Partners LP increased its position in shares of BioCryst Pharmaceuticals by 16.0% during the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after purchasing an additional 412,347 shares during the period. Northern Trust Corp increased its position in shares of BioCryst Pharmaceuticals by 7.7% during the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock valued at $15,077,000 after purchasing an additional 143,986 shares during the period. Eversept Partners LP increased its position in shares of BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after purchasing an additional 1,444,907 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in BioCryst Pharmaceuticals by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock valued at $14,890,000 after buying an additional 91,998 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 1.9%

Shares of NASDAQ BCRX traded up $0.20 during midday trading on Friday, reaching $10.59. 3,608,168 shares of the company's stock traded hands, compared to its average volume of 3,026,377. The stock's 50 day simple moving average is $8.38 and its 200-day simple moving average is $8.05. BioCryst Pharmaceuticals, Inc. has a one year low of $5.92 and a one year high of $11.11. The company has a market cap of $2.22 billion, a price-to-earnings ratio of -17.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the company posted $0.28 earnings per share. The company's revenue was up 40.8% on a year-over-year basis. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on BCRX. Needham & Company LLC boosted their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.